Skip to main content

Market Overview

Pieris Pharmaceuticals: Q1 Earnings Insights



Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share increased 0.00% over the past year to ($0.07), which beat the estimate of ($0.17).

Revenue of $15,633,000 rose by 17.89% from the same period last year, which beat the estimate of $6,470,000.


Earnings guidance hasn't been issued by the company for now.

Pieris Pharmaceuticals hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: May 17, 2021

Time: 08:00 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $3.64

52-week low: $1.70

Price action over last quarter: down 26.85%

Company Overview

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.


Related Articles (PIRS)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at